Bromantane
Also known as: Ladasten, Bromantan
Actoprotector | Dopamine Upregulation & Adaptive Energy
Overview
Bromantane (Ladasten) is a synthetic adamantane derivative developed in Russia during the 1980s as part of a military research program aimed at improving soldiers' physical and mental performance under extreme conditions. It was officially registered in Russia in 2002 as an anxiolytic and actoprotector -- a pharmacological class defined by the ability to enhance physical work capacity and mental performance under stressful conditions without the hyperactivation or crash associated with traditional stimulants. Unlike amphetamines, methylphenidate, or modafinil, bromantane does not directly block reuptake or trigger release of monoamines. Instead, it upregulates the gene expression of key enzymes in the dopamine biosynthetic pathway, producing a sustained, physiological increase in dopamine availability. This mechanism gives it a uniquely smooth, non-depleting profile that has made it increasingly popular in the international nootropic community for sustained cognitive energy, motivation, and stress resilience.
Key benefits
- Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
- Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
- Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
- Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
- Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
- Smooth onset and offset with no crash or rebound effects
Mechanism of action
Bromantane's mechanism of action is fundamentally different from conventional stimulants and most nootropic compounds. Its primary action is the upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) gene expression in the striatum and other dopaminergic brain regions. Tyrosine hydroxylase is the rate-limiting enzyme in dopamine synthesis, converting L-tyrosine to L-DOPA, while AADC converts L-DOPA to dopamine. By increasing the transcription of these enzymes, bromantane enhances the brain's endogenous capacity to produce dopamine rather than forcing release of existing stores or blocking their reuptake. This results in a gradual, sustained elevation of dopaminergic tone without the rapid depletion, tolerance, or rebound effects characteristic of releasers or reuptake inhibitors. Additionally, bromantane has documented anxiolytic properties, likely mediated through GABAergic facilitation and modulation of hippocampal activity, which contribute to its stress-protective and actoprotective effects. The compound also demonstrates mild serotonergic activity, which may further support its anxiolytic profile. This dual action -- enhanced dopaminergic drive combined with anxiolysis -- is what distinguishes bromantane from virtually all other cognitive enhancers and gives it the 'calm energy' quality users frequently describe.
Molecular data
- Type
- Adamantane-bromophenyl derivative (C16H20BrN)
- Half-life
- ~11 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cognitive Enhancement
Anxiolytic / Adaptogenic
Physical Performance
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 50 mg | Once daily in the morning | — |
| — | 100 mg | Once daily in the morning | — |
| — | 50-100 mg | Once daily in the morning | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Insomnia or difficulty falling asleep (if taken too late in the day)
- Mild anxiety or restlessness at higher doses (above 100 mg)
- Mild headache (uncommon, typically transient)
Rare side effects
- Gastrointestinal discomfort (nausea, mild stomach upset)
- Allergic skin reactions
- Elevated liver enzymes with prolonged high-dose use (theoretical, based on adamantane class effects)
Contraindications
- Known hypersensitivity to bromantane or adamantane derivatives
- Pregnancy and breastfeeding (insufficient safety data)
- Severe hepatic impairment
- Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)
Monitoring
- Sleep quality: ensure dosing timing does not interfere with sleep
- Anxiety levels: monitor for paradoxical anxiety, especially at higher doses
- Liver function: consider periodic monitoring with prolonged use, as with other adamantane compounds
- Mood and motivation: track response over the first 2-4 weeks to assess cumulative benefit
References
Primary literature and clinical-trial data informing this entry.